Lenz Therapeutics Beats Q2 Revenue Estimates by 148% Driven by VIZZ Sales

Key Facts

1Lenz Therapeutics reported Q2 revenues of $5.5 million, significantly beating analyst estimates by 148.24%.

2The company posted a loss of $1.02 per share, which was narrower than expected.

3Piper Sandler lowered its price target for Lenz Therapeutics to $7.00 from a previous $12.00.

In a move reflecting the accelerating growth within the specialized pharmaceutical sector, Lenz Therapeutics announced robust financial results for the second quarter of 2026. According to reports, the company generated $5.5 million in revenue, significantly beating analyst estimates by 148.24%, driven by the commercial launch of its VIZZ treatment and licensing agreements. The company also posted a loss of $1.02 per share, which was narrower than previously anticipated.

This strong performance was primarily fueled by $3.8 million from license agreements and $1.7 million in product sales, with approximately 27,000 monthly packs of VIZZ sold, marking a 9% volume increase over the first quarter. Despite these positive results, Piper Sandler lowered its price target for LENZ to $7.00 from $12.00, as the stock has traded between a 52-week low of $4.68 and a high of $50.40 per analyst data.

Looking ahead, the company is focusing on the commercial expansion of VIZZ through new marketing strategies and telehealth options to boost prescription activity. While current price data is unavailable at this snapshot, investors are watching for sustained sales growth following July's performance, amid a broader market context influenced by recent economic data such as US jobless claims and inflation figures reported on August 7, 2026.

Sources:

Financial Modeling Prep